Skip to main content
OpenTrials
Completed

NCT Number: NCT04375761

COVID-19: Human Epidemiology and Response to SARS-CoV-2

The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death.

The purpose of this study is to:

* Determine the prevalence of SARS-CoV-2 carrier status over time in children and parents * Determine the prevalence of antibody development over time in children and parents * Compare carrier status and antibody development for children with asthma and/or other atopic conditions (e.g. eczema) versus children without asthma and/or other atopic conditions * Investigate the presence of SARS-CoV-2 exposure in historical samples from enrolled participants

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronavirus Disease 2019 (COVID-19) COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections SARS-CoV-2 Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Hospital Colorado: Inner City Asthma Consortium (ICAC) Site, Aurora, Colorado, United States

Loading trial locations.

About this study

The study population will include children that are participants in NIH-funded cohort studies and their families (household contacts).The intent is to recruit families that have experience with the collection of respiratory samples.

The objective of this surveillance study is to identify the rate of infection in children and what, if any effect, atopy has on the SARS-CoV-2 carrier status.

The initial surveillance interval for participants will be 6 months and, depending upon the findings, may be extended. During surveillance, biological samples will be collected by the family at established intervals and symptom and exposure surveys will be completed remotely via a smart phone, on-line, or phone communications at the time the biological samples are collected.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Household members who meet all of the following criteria are eligible for enrollment as study participants:

  • The index participant, defined as an individual who either is or has been a participant in an NIH-funded clinical research study from which information on respiratory conditions, including asthma, and other atopic and allergic diseases is available, is:
  • ≤21 years of age, and
  • Lives with caregiver(s).
  • The index participant and/or caregiver understands the study procedures and is willing to conduct these procedures at home;
  • Have the ability to use either a computer or a smart phone to link to and respond to the study questionnaires:

--Exception: When the family is willing to speak with a study member to answer the questionnaires in the event of not having access to a computer or a smart phone.

  • The index participant and caregiver will reside in the United States, including Puerto Rico, for the duration of the study;
  • The index participant will live with the caregiver for at least 50% of the time for the duration of the study;
  • An English or Spanish speaker is available to:
  • Serve as the primary contact, and
  • As the person who will be responsible for the completion of questionnaires and the collection of study biological samples; and,
  • To participate as a sibling (of the index participant), must be under 21 years of age and live in the same home as the index participant and caregiver.

Exclusion criteria

-Past or current medical problems, which, in the opinion of the site investigator may:

  • Pose risks from participation in the study
  • Interfere with the participant's ability to comply with study requirements, or
  • Impact the quality or interpretation of the data obtained from the study.

Treatment and study plan

Collection of Biological Samples

Procedure

Biological samples will be collected throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. All biological samples (e.g. nasal swabs, peripheral blood, stool) will be collected by the caregiver at home using materials provided to the family. At the end of study, additional samples (e.g. nasal secretion and/or saliva samples) may be collected by the family or study staff at a site visit, if feasible.

Symptom and Exposure Surveys

Procedure

Symptom and exposure surveys (questionnaires) will be completed throughout the study at regular intervals (every 2 weeks) in addition to when illness event(s) occur. The primary household contact/caregiver will be the designee for ensuring timely questionnaires completion and submission for all household study participants.

Other names: Symptom and Exposure Questionnaires

Primary outcomes

  1. Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period

    Time frame: Baseline through end of study (24 or 28 weeks, depending on if a participant agreed to do the extension)

    Nasal samples were analyzed to determine whether a participant ever tested positive for SARS-CoV-2 or not over the course of the study. Kaplan-Meier was used to estimate survival probabilities at timepoints throughout the study. Participants were censored if they did not test positive for SARS-CoV-2 by the end of follow-up. The last positive nasal swab occurred at day 212.

Secondary outcomes

  1. Percent of Index Participants and Their Household Contacts With Detectable SARS-CoV-2-Specific Antibodies in Serum Over the Study/Surveillance Period

    Time frame: Up to Week 24

    Included: Participants currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts.

    Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).

  2. Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples With Asthma and Other Atopic Disease Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period

    Time frame: Up to Week 24

    Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.

    Testing method: Positive test result(s) for SARS-CoV-2 RNA in nasal samples.

  3. Percent of Index Participants With Asthma and Other Atopic Disease With Detectable SARS-CoV-2-Specific Antibodies in Serum Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period

    Time frame: Through study completion, an average of 24 Weeks

    Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.

    Outcome definition: Detectable SARS-CoV-2-specific antibodies in serum biological specimen(s).

  4. Changes in the Nasal Transcriptome Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period

    Time frame: Up to Week 24

    Nasal samples of participants currently or previously enrolled in NIH-funded studies who fulfill inclusion criteria (index participant) and their family/household contacts that test positive for SARS-CoV-2, will undergo transcriptome analysis.

    Total RNA will be isolated for cDNA synthesis and amplification. Differential gene expression analysis be pursued.

  5. Changes in the Nasal Transcriptome Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants With Asthma and Other Atopic Disease Compared to Index Participants Without Atopic Disease Over the Study/Surveillance Period

    Time frame: Up to Week 24

    Nasal samples of index participants that test positive for SARS-CoV-2 will be evaluated by transcriptome analysis. Differential gene expression analysis at different timepoints in the disease process will be analyzed.

    Definition of index participant(s): Prior and/or current NIH-funded clinical research study participant(s) who fulfill inclusion criteria.

  6. Symptoms Associated With Detection of SARS-CoV-2 in Nasal Samples Among Index Participants and Their Household Contacts Over the Study/Surveillance Period

    Time frame: Up to Week 24

    An analysis of symptoms associated with positive SARS-CoV-2 RNA tests in nasal samples will be conducted.

    Included in analysis: Index participants and their household contacts.

  7. Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples Using Topical Steroids Compared to Index Participants That Are Not Using Topical Steroids Over the Study/Surveillance Period

    Time frame: Up to Week 24

    Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.

    Tests: Positive for SARS-CoV-2 RNA in nasal samples

  8. Number of Index Participants With SARS-CoV-2 Detection in Nasal Samples Using Topical, Oral, or Inhaled Steroids Compared to Index Participants That Are Not Using Topical, Oral, or Inhaled Steroids During the Study/Surveillance Period

    Time frame: Up to Week 24

    Index participants: Those currently or in the past enrolled in NIH-funded studies who fulfill inclusion criteria.

    Tests: Positive for SARS-CoV-2 RNA in nasal samples.

  9. Analysis of Factors, Baseline and Prior History, for Possible Association With the Cumulative Incidence of SARS-COV-2 Detection in Nasal Samples: Index Participants and Their Household Contacts Over the Study/Surveillance Period

    Time frame: Baseline, Week 24

    An exploratory analysis will be conducted for detection of possible associations, focusing on baseline demographic and environment factors and/or history of bronchiolitis prior history with the cumulative incidence of SARS-CoV-2 detection in nasal samples Test: Positive for SARS-CoV-2 RNA in nasal samples.

Sponsors and collaborators

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Nih

Collaborators

  • Rho Federal Systems Division, Inc.

Registry information

Official study title

Human Epidemiology and Response to SARS-CoV-2 (DAIT-COVID-19-001)

Acronym: HEROS

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 5, 2020
Registry last updated
Aug 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.